8-K: Jushi Holdings Reports FY25 Revenue Growth, Debt Refinancing

Jushi Holdings Inc. announced its fourth quarter and full year 2025 financial results, reporting a 2% year-over-year revenue increase and a significant debt refinancing extending maturities to 2029.

Summary

• Total revenue for the full year 2025 reached $262.9 million, marking a 2% increase year-over-year, driven by new store openings.
• The Company reported a net loss of $68.6 million for the full year 2025, compared to a net loss of $48.8 million in 2024.
• Adjusted EBITDA for the full year 2025 was $50.3 million, an 8.8% increase from $46.2 million in 2024, with an Adjusted EBITDA margin of 19.1%.
• For the fourth quarter of 2025, total revenue was $68.3 million, up 3.8% year-over-year.
• Q4 2025 net loss was $15.6 million, compared to $12.5 million in Q4 2024.
• Q4 2025 Adjusted EBITDA significantly increased by 74% year-over-year to $13.9 million, achieving an Adjusted EBITDA margin of 20.4%.
• Subsequent to year-end, Jushi refinanced approximately $132.3 million of existing debt through a new $160.0 million 12.5% secured term loan due in 2029, enhancing liquidity and strengthening the balance sheet.
• Virginia adult-use cannabis legislation passed by the General Assembly, establishing a regulated retail market with sales projected to begin January 1, 2027, subject to the Governor's approval.
• The retail footprint expanded with eight new store openings since Q3 2024 through the end of 2025, bringing the total to 42 operating dispensaries.
• Jushi-branded products accounted for 58% of retail revenue across its five vertical markets in Q4 2025, an increase of 332 basis points year-over-year.
• Cash, cash equivalents, and restricted cash stood at $26.6 million as of December 31, 2025.
• Net cash flows provided by operations were $17.7 million for FY 2025 and $6.1 million for Q4 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive report, driven by strong Q4 Adjusted EBITDA growth, strategic debt refinancing, and the significant future market opportunity presented by Virginia's adult-use legislation, despite an increased full-year net loss.

Positives

• Full Year 2025 revenue increased by 2.1% to $262.9 million, reflecting contributions from new store openings.
• Q4 2025 revenue increased by 3.8% to $68.3 million compared to Q4 2024.
• Full Year 2025 Adjusted EBITDA increased by 8.8% to $50.3 million, demonstrating improved operational efficiency.
• Q4 2025 Adjusted EBITDA saw a significant 74% increase to $13.9 million, with the Adjusted EBITDA margin improving to 20.4% from 12.2% year-over-year.
• Successful refinancing of approximately $132.3 million in existing debt post-year-end, extending maturities to 2029 and enhancing liquidity and financial flexibility.
• Virginia adult-use cannabis legislation passed, establishing a regulated retail market with sales expected to commence January 1, 2027, presenting a significant future growth opportunity.
• Expanded retail footprint with eight new store openings since Q3 2024, ending 2025 with 42 operating dispensaries.
• Jushi-branded products represented 58% of retail revenue in Q4 2025, an increase of 332 basis points year-over-year, indicating strong brand penetration.
• Gross profit margin in Q4 2025 increased to 41.9% from 38.6% in Q4 2024, driven by higher production volumes, improved product quality, and stronger performance at grower-processor facilities.
• Net cash flows provided by operations were positive at $17.7 million for FY 2025 and $6.1 million for Q4 2025.
• Received $10.6 million related to employee retention credit claims, including interest, for FY 2025.

Negatives

• Full Year 2025 net loss increased to $68.6 million from $48.8 million in FY 2024, representing a 40.6% increase.
• Q4 2025 net loss increased to $15.6 million from $12.5 million in Q4 2024, a 24.8% increase.
• Full Year 2025 gross profit margin decreased to 43.4% from 45.9% in FY 2024, primarily due to ongoing competitive pricing pressure requiring higher discounting.
• Wholesale revenue decreased by $2.2 million for FY 2025, mainly due to lower demand from wholesale partners in Virginia and limited product availability for third-party customers during the first half of 2025.
• Interest expense, net, increased to $40.8 million for FY 2025 and $10.4 million for Q4 2025.
• Reported a fair value loss on derivatives of $5.1 million for FY 2025.
• Total liabilities increased to $537.686 million as of December 31, 2025, from $490.555 million as of December 31, 2024.
• Accumulated deficit increased to $627.212 million as of December 31, 2025, from $558.621 million as of December 31, 2024.

Risks

• The cannabis industry and the Company have a limited operating history.
• Risks are associated with managing the Company's growth, including potential future impairment of goodwill or intangibles acquired and post-closing disputes related to acquisitions or dispositions.
• There are risks related to the continued performance, expansion, and optimization of existing operations.
• Anticipated openings of additional dispensaries or relocation of existing dispensaries are subject to licensing approval.
• The Company has a history of operating losses and negative operating cash flows.
• Increasing competition exists within the cannabis industry.
• Risks inherent in an agricultural business, such as the effects of natural disasters, can impact operations.
• The Company relies on the expertise and judgment of its senior management.
• Risks are associated with cannabis products manufactured for human consumption, including potential product recalls.
• There is limited research and data relating to cannabis.
• Constraints exist on marketing cannabis products.
• The Company faces risks of litigation and insurance-related risks.
• Public opinion and perception of the cannabis industry can impact the business.
• Risks are related to the economy generally, including inflation, rising cost of capital, and stock market instability.
• The Company faces risks from fraudulent activity by employees, contractors, and consultants.
• Risks relate to the Company's current amount of indebtedness and its ability to reduce or refinance debt obligations.
• Reliance on key inputs, suppliers, skilled labor, and third-party service provider contracts poses risks.
• Risks of supply shortages or supply chain disruptions exist.
• Risks relating to pandemics and forces of nature can affect operations.
• Risks are related to the enforceability of contracts.
• The U.S. regulatory landscape and enforcement related to cannabis, including political risks, present challenges.
• Risks relating to anti-money laundering laws and regulation are present.
• Cannabis-related tax risks and challenges from governmental authorities with respect to Employee Retention Tax Credits (ERTC) are a concern.
• Other governmental and environmental regulations can impact the business.
• Risks are related to proprietary intellectual property and potential infringement by third parties.
• Sales of a significant amount of shares by existing shareholders could impact stock price.
• The market for the Company's securities is limited.
• Risks relate to the need to raise additional capital either through debt or equity financing.
• Costs are associated with the Company being a publicly-traded company and a U.S. and Canadian filer.
• Risks are related to co-investment with parties with different interests to the Company.
• Conflicts of interest and related party transactions are potential risks.
• Cybersecurity risks are present.
• Risks are related to the Company's critical accounting policies and estimates.

Future Outlook

Management is encouraged by the progress toward adult-use cannabis in Virginia, believing the Company's existing cultivation, manufacturing, and retail infrastructure positions it well to participate in what could be a meaningful expansion of that market. The focus for 2026 remains on disciplined execution, thoughtful capital allocation, and continuing to build a scalable platform capable of generating sustainable profitability and long-term value for shareholders.

Management Comments

• "As we reflect on 2025, it was a year defined by execution, operational efficiency, and disciplined decision-making."
• "The progress we delivered across cultivation, retail, and commercial demonstrates that those efforts are taking hold."
• "Improvements in yields, potency, and consistency of cultivars across our grower-processor facilities, combined with continued retail execution and growth in our branded product portfolio, contributed to stronger margins and meaningful expansion in Adjusted EBITDA during the fourth quarter."
• "Subsequent to year end, we further strengthened our balance sheet through the refinancing of our existing senior secured term loan and second lien notes, extending maturities and enhancing our liquidity position."
• "We believe this transaction improves our financial flexibility and positions the Company to continue investing in high-return opportunities while maintaining disciplined capital allocation."
• "The operational progress we made in 2025 laid a strong foundation for the future, and we are excited about the opportunities ahead in 2026."
• "In particular, we are encouraged by the progress toward adult-use cannabis in Virginia and believe our existing cultivation, manufacturing, and retail infrastructure positions us well to participate in what could be a meaningful expansion of that market."
• "As we move into 2026, our focus remains on disciplined execution, thoughtful capital allocation, and continuing to build a scalable platform capable of generating sustainable profitability and long-term value for our shareholders."

Industry Context

StockSavvy.ai notes that the passage of Virginia's adult-use cannabis legislation is a significant positive development for Jushi, given its existing cultivation, manufacturing, and retail infrastructure in the state. This aligns with a broader trend of increasing state-level cannabis legalization across the U.S., which is expected to drive market growth for multi-state operators. The refinancing of debt also reflects a common strategy among cannabis companies to manage high capital costs and extend financial runways in a complex regulatory environment.

Comparison to Industry Standards

• The filing does not provide specific comparisons to industry benchmarks or competitor results.

Legal Proceedings

• Ongoing dispute regarding promissory notes issued to Sammartino in connection with the acquisition of Natures Remedy, where the company currently has no obligation to repay these notes.

Related Party Transactions

• An entity affiliated with Jim Cacioppo (CEO, Chairman, Founder) and Denis Arsenault (significant equity holder) participated in the $160.0 million secured term loan refinancing.
• Related party principal amounts of $41.109 million in non-current debt as of December 31, 2025 (compared to $35.296 million as of December 31, 2024).

Stakeholder Impact

• Shareholders: Potential for long-term value creation through strategic debt refinancing, operational improvements, and expansion into new adult-use markets like Virginia. However, increased net loss and accumulated deficit could be a concern.
• Creditors: Improved debt maturity profile with the new 2029 term loan, reducing near-term refinancing risk.
• Employees: Continued focus on operational efficiency and growth could stabilize employment, though ongoing optimization efforts are noted.
• Customers: Expanded retail footprint and continued product innovation (280 new SKUs) aim to enhance product availability and choice.
• Suppliers: Potential for increased demand with market expansion, but competitive pricing pressures could impact supplier negotiations.

Next Steps

• Continue investing in high-return opportunities.
• Maintain disciplined capital allocation.
• Focus on disciplined execution.
• Continue building a scalable platform capable of generating sustainable profitability and long-term value for shareholders.
• Participate in the anticipated expansion of the Virginia adult-use cannabis market (expected sales start January 1, 2027).
• Host a conference call on March 31, 2026, at 4:00 p.m. ET to discuss financial results.

Key Dates

Recommendation

While Jushi Holdings demonstrated strong Q4 Adjusted EBITDA growth and strategically refinanced its debt, extending maturities, the full-year net loss widened significantly. The Virginia adult-use market presents a substantial future opportunity, but its impact is not immediate. The company is making operational strides, but the overall financial picture remains mixed with ongoing competitive pressures and a substantial accumulated deficit. A "hold" recommendation reflects cautious optimism, acknowledging positive strategic moves and operational improvements while awaiting sustained profitability and clearer market traction from new initiatives.

Keywords

cannabis, multi-state operator, MSO, Jushi Holdings, JUSH, JUSHF, financial results, Q4 2025, FY 2025, revenue, Adjusted EBITDA, debt refinancing, Virginia adult-use, dispensary expansion, cannabis market, cultivation, retail cannabis